Clinical

Dataset Information

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer


ABSTRACT: Primary objectives: • to gather preliminary evidence of superior activity, of RO5083945 added to FOLFIRI versus FOLFIRI + cetuximab in terms of progression free survival (PFS) in patients with KRAS WT colorectal cancer • to gather preliminary evidence of superior activity, of RO5083945 added to FOLFIRI versus FOLFIRI alone in terms of progression free survival (PFS) in patients with KRAS mutant colorectal cancer Primary endpoints: The primary variable is PFS defined as the time between randomization and date of first documented disease progression or death, whichever occurs first.

DISEASE(S): Colorectal Cancer Metastatic,Metastatic Colorectal Cancer, Kras Wild-type (wt) Or Mutant, With Disease Progression After First Line Treatment With An Oxaliplatin-containing Regimen

PROVIDER: 2528754 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR